The effect of systemically administered 5a-HSA on TGFβ activation in the tumor microenvironment was then analyzed in another model based on TS/A mammary adenocarcinoma cells implanted subcutaneously in immunocompetent mice. This evidence concerns the gene TGFB1 and neoplasm.